Physician profile
Kavish R Patidar
NPI 1649531062
$21,703.47
in general payments reported to CMS, 2019-2025
12 companies · $21K in 2025
The $21K reported for 2025 was more than what 83% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.85 · 2021: $32.27 · 2023: $166 · 2024: $261 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $1,635 · Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,962.50 |
| Travel and Lodging | $1,635.19 |
| Food and Beverage | $1,060.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $18,509.56 | 2023-2025 | Terlivaz |
| Novo Nordisk INC | $2,766.80 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $174.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $68.21 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $42.55 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.06 | 2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $22.80 | 2025 | |
| Medtronic, INC. | $19.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.41 | 2024 | Entyvio |
| Ardelyx, INC. | $14.76 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $12.85 | 2019 | |
| Ambu INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavish Patidar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.